



NEONATAL MEDICATION PROTOCOLS

DIAZOXIDE
 Created by: NCCU
 Date for review: Aug 2016

NCCU Clinical Guidelines
 KEMH/PMH
 Perth, Western Australia

DRUG:	DIAZOXIDE
PRESENTATION:	Oral suspension: 50mg/mL (SAS approval required)
ACTION & INDICATION:	Increases blood glucose concentration by inhibiting pancreatic insulin secretion. It may increase the hepatic output of glucose. For (i) profound or prolonged hypoglycaemia unresponsive to other forms of therapy, or (ii) idiopathic hypoglycaemia of infancy.
DOSE:	Initial dose: 5 mg / kg / dose twice daily Taper dose according to response Usual maintenance dose 1.5-3 mg/kg 2-3 times daily Maximum dose: 15 mg / kg / day.
ADMINISTRATION:	Oral: May be given at any time with regard to feeds.
ADVERSE EFFECTS:	Hypotension – monitor BP pre-dose and 30 minutes post dose, continue until stabilised for 48 hours then twice daily. Hyperbilirubinaemia Thrombocytopenia Hyperglycaemia Dysrhythmias Commonly causes fluid retention
COMMENTS:	Use cautiously in patients with impaired cardiac or cerebral circulation. Use of the mixture is restricted to patient's for whom SAS approval has been obtained (contact the ward pharmacist).
REFERENCES:	BNF for Children 2013 Neofax 2012
DATE:	August 2013